Moleculin says Annamycin preclinical data show CD8+ T cell-mediated activity in pancreatic cancer models

MBRX•2026-09-25

Moleculin Biotech said preclinical pancreatic cancer findings suggest Annamycin’s antitumor effect is partly driven by CD8+ T cells, supporting a possible combination strategy with immunotherapies.

Moleculin says Annamycin preclinical data show CD8+ T cell-mediated activity in pancreatic cancer models

1. Preclinical findings

Related News

U.S. stocks on the move: Microsoft, 3M, Twilio

Trump says Treasury's Bessent will not be his AI czar

Copper inches higher on weaker dollar, tight Chinese supplies

Nasdaq halts trading for volatility at 12:45 p.m.

US refiner Phillips 66 is using AI to predict outages and boost processing, executive says